
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is a biopharmaceutical firm with a strong focus on developing and commercializing cancer treatments, including their approved drug Cabometyx and upcoming catalysts such as the STELLAR-316 and STELLAR-304 trials. With a diverse pipeline and focus on small molecule-based approaches, the company has positioned itself for potential long-term success, although there are inherent risks in the development of oncology drugs.
Bears say
Exelixis is facing a major FDA decision on December 3 and the approval of Cometriq for 3L+ mCRC could potentially open up a ~$1B market opportunity, making it a key driver for the company's future growth and valuation. Despite mixed results in a recent study, the company's strong cabo scripts and increasing sales expectations could also provide a boost to its stock price. However, concerns remain around the effectiveness of its drug in patients with liver metastases and the potential for consolidation in the highly competitive market, leading to a negative outlook on the stock. In addition, the current price target for the stock is at $55, reflecting a potentially overvalued stock.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares